FTC to Sue Drug Managers Over Insulin Prices
The Federal Trade Commission is planning to take legal action against the three largest pharmacy-benefit managers for their practices in negotiating drug prices, particularly for insulin. The FTC’s investigation, which spanned two years, looked into allegations that these companies manipulate patient choices to favor more expensive medications. The agency intends to file lawsuits specifically addressing the rebates they facilitate with drug manufacturers. Additionally, the FTC is examining the involvement of insulin manufacturers in these negotiations.